Skip Navigation

Meet Our Specialists

  • Our specialists: pioneering new paths to treatment

    Neuroendocrine and carcinoid tumors are challenging diseases. At the Neuroendocrine and Carcinoid Tumors Program, our specialists are making breakthrough discoveries in every discipline:

    • Our medical oncologists are improving the use of chemotherapy and targeted agents through clinical trials and new treatment approaches, such as with therapies that harness the immune system to fight the cancer.
    • Our surgeons offer the full range of advanced surgery, and are pioneering the newest surgical approaches, including laparoscopic and robotic surgeries, and operations to remove larger tumors that more intimately involve surrounding blood vessels.
    • Our radiologists are pioneering the use of imaging tests to allow optimal diagnosis and treatment of patients with neuroendocrine and carcinoid tumors.
    • Our gastroenterologists are identifying new treatment techniques.
    • Our pathologists work closely with surgeons and endoscopists to evaluate tissue samples in real-time, leading to faster, more accurate diagnoses.
    • Our radiation oncologists are discovering better combinations of radiation and systemic therapies, including newer targeted agents. They are pioneering stereotactic radiation therapy to treat localized tumors with less damage to surrounding tissues.
    • Our endoscopists are using innovative advanced endoscopic techniques to evaluate tumors and relieve obstructions.
    • Our scientists are working to understand the fundamental biology of these cancers to identify new ways to prevent and treat these diseases in our patients.

    Meet Our Leaders

  • Jennifer Chan, MD, MPH

    Jennifer Chan, MD, MPH

    Medical Oncology
    Anal Cancer | Biliary Cancer
    Thomas E. Clancy, MD, FACS

    Thomas E. Clancy, MD, FACS

    Surgical Oncology
    Kimberly Perez, MD

    Kimberly Perez, MD

    Medical Oncology
    Anal Cancer | Biliary Cancer
  • More About Our Leaders

    Jennifer Chan MD, MPH, is clinical director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber and an assistant professor of Medicine at Harvard Medical School. Chan has broad expertise in the treatment of patients with neuroendocrine tumors. In addition to her clinical practice, she has lectured widely and published numerous articles on treatment approaches for patients with pancreatic neuroendocrine and carcinoid tumors. Chan has played a leading role in the development of novel neuroendocrine tumor therapies, and has served as the principal investigator of several investigator-initiated clinical trials. She serves on the executive committee of the North American Neuroendocrine Tumor Society and on the Neuroendocrine Tumor Task Force of the National Cancer Institute.

    Kimberly Perez, MD, is a member of the DF/HCC Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She received her undergraduate training at Georgetown University in Washington, DC, and received her MD from George Washington University in Washington, DC. She completed her residency and fellowship training at Rhode Island Hospital in 2010. After completing her fellowship, she joined the medical faculty at Warren Alpert School of Medicine at Brown University and served as a Gastrointestinal Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined the faculty at Dana-Farber Cancer Institute in 2015 and is currently an Assistant Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute.

    Thomas E. Clancy, MD, is a surgical oncologist specializing in pancreaticobiliary and liver surgery at Brigham and Women's Hospital and Dana-Farber Cancer Institute, and is co-director of DF/BWCC's Pancreas and Biliary Tumor Center. He obtained his medical degree from Harvard Medical School, followed by general surgical residency and surgical oncology fellowships at Brigham and Women's Hospital. Clancy's clinical focus is the treatment of gastrointestinal malignancies, specifically pancreatic, biliary, and liver tumors. In addition, Clancy has a specific clinical and research interest in neuroendocrine tumors. A high-volume clinical surgical oncologist, Clancy has expertise in the surgical management of primary small intestinal and pancreatic neuroendocrine tumors and resection of neuroendocrine tumor liver metastases. Clancy has been a leader in the development and adoption of minimally-invasive treatment techniques, including robotic pancreatectomy.

    See the complete list of our gastrointestinal cancer specialists.